Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 249,688		$ 249,688
Operating expenses:
Research and development	2,202,657	$ 6,811,609	3,459,199	$ 10,901,186
General and administrative	1,698,712	15,633,738	5,064,673	19,619,036
Acquired in-process research and development		76,020,184		76,020,184
Total operating expenses	3,901,369	98,465,531	8,523,872	106,540,406
Loss from operations	(3,651,681)	(98,465,531)	(8,274,184)	(106,540,406)
Other income:
Interest income, net	336,221	52,491	592,631	54,462
Foreign currency gain	56,363	154,566	42,566	290,777
Total other income	392,584	207,057	635,197	345,239
Net loss	(3,259,097)	(98,258,474)	(7,638,987)	(106,195,167)
Other comprehensive loss:
Foreign currency translation	(73,420)	157,655	(11,464)	92,150
Total comprehensive loss	$ (3,332,517)	$ (98,100,819)	$ (7,650,451)	$ (106,103,017)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.87)	$ (86.72)	$ (2.18)	$ (95.31)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.87)	$ (86.72)	$ (2.18)	$ (95.31)
Weighted-average common shares outstanding, basic (in shares)	3,731,571	1,133,092	3,497,329	1,114,189
Weighted-average common shares outstanding, diluted (in shares)	3,731,571	1,133,092	3,497,329	1,114,189